Skip Navigation

Annals of Oncology 2008 19(9):1517; doi:10.1093/annonc/mdn600
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Matrix metalloproteinase expression and breast cancer outcomes
 
Matrix metalloproteinases (MMPs) have been implicated in cancer invasion and metastasis. Consequently, several MMPs have been investigated for potential prognostic value as well as targets for antimetastatic therapy. In this issue, McGowan and Duffy [p. 1566] report the results of a study that aimed to use a publicly available database to relate messenger RNA expression levels for 17 different MMPs to tumor characteristics and . . . [Full Text of this Article]


   Intensive induction chemoradiotherapy plus maintenance gemcitabine vs. gemcitabine alone for pancreatic cancer
 

   cMET expression in NSCLC patients treated with EGFR tyrosine kinase inhibitors
 

   Palifermin for the prevention of high-dose methotrexate-induced oral mucositis
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?